Prevalence of psychoactive drug use in patients hospitalized for acute cardiac events: Rationale and design of the ADDICT-ICCU trial, from the Emergency and Acute Cardiovascular Care Working Group and the National College of Cardiologists in Training of the French Society of Cardiology - 10/11/22
for the ADDICT-ICCU investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Graphical abstract |
Study design of the ADDICT-ICCU study, a nationwide prospective multicentre study involving 39 centres throughout France, evaluating the prevalence of psychoactive drugs detected in consecutive patients hospitalized in an intensive cardiac care unit (ICCU) for an acute cardiovascular event. Detection of illicit (cannabinoids, cocaine, amphetamines, ecstasy, heroin and other opioids) and non-illicit (barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine) psychoactive drugs will be performed through urine analysis using NarcoCheck® (Kappa City Biotech SAS, Montluçon, France) within 2hours of admission to the ICCU. MACE: major adverse cardiovascular events.
Highlights |
• | Psychoactive drug use is a public health concern. |
• | Psychoactive drug use is prevalent and increases the risk of CV events. |
• | Psychoactive drug use can induce acute CV events. |
• | Prevalence of psychoactive drug use in patients hospitalized in an ICCU is unknown. |
• | ADDICT-ICCU will assess this prevalence by systematic urinary drug screening. |
• | Consecutive patients hospitalized in ICCU for an acute CV event will be screened. |
Summary |
Background |
Psychoactive drugs, including illicit drugs, are associated with an increased rate of cardiovascular events. The prevalence and outcome of patients using these drugs at the time of admission to an intensive cardiac care unit is unknown.
Aim |
To assess the prevalence of psychoactive drugs detected in consecutive patients hospitalized in an intensive cardiac care unit for an acute cardiovascular event.
Methods |
This is a nationwide prospective multicentre study, involving 39 centres throughout France, including all consecutive patients hospitalized in an intensive cardiac care unit within 2weeks. Psychoactive drug use will be assessed systematically by urine drug assay within 2hours of intensive cardiac care unit admission, to detect illicit (cannabinoids, cocaine, amphetamines, ecstasy, heroin and other opioids) and non-illicit (barbiturates, benzodiazepines, tricyclic antidepressants, methadone and buprenorphine) psychoactive drugs. Smoking will be investigated systematically by exhaled carbon monoxide measurement, and alcohol consumption using a standardized questionnaire. In-hospital major adverse events, including death, resuscitated cardiac arrest and cardiogenic shock, will be recorded. After discharge, all-cause death and major adverse cardiovascular events will be recorded systematically and adjudicated at 12months of follow-up.
Results |
The primary outcome will be the prevalence of psychoactive drugs detected by systematic screening among all patients hospitalized in an intensive cardiac care unit. The in-hospital major adverse events will be analysed according to the presence or absence of detected psychoactive drugs. Subgroup analysis stratified by initial clinical presentation and type of psychoactive drug will be performed.
Conclusions |
This is the first prospective multicentre study to assess the prevalence of psychoactive drugs detected by systematic screening in consecutive patients hospitalized for acute cardiovascular events.
Le texte complet de cet article est disponible en PDF.Keywords : Psychoactive drug, Illicit drug, Addiction, Intensive cardiac care unit, Prevalence
Abbreviations : EMCDDA, FACE, ICCU, MACE, QFR
Plan
| ☆ | Tweet: The ADDICT-ICCU trial, an original prospective study about the prevalence of physchoactive drug use in patients admitted to intensive cardiac care unit! Twitter address: @PezelT. |
Vol 115 - N° 10
P. 514-520 - octobre 2022 Retour au numéro
Article précédent
- Five-year clinical outcomes using the bioresorbable vascular scaffold: Insights from the FRANCE ABSORB registry
- Quentin Landolff, Thierry Lefèvre, Jean Fajadet, Joel Sainsous, Thibault Lhermusier, Simon Elhadad, François Tarragano, Sylvain Ranc, Saïd Ghostine, Guillaume Cayla, Frédéric Marco, Philippe Garot, Luc Maillard, Pascal Motreff, Nicolas Delarche, Axel De Labriolle, Michel Pansieri, Jean-François Morelle, Pierre Cazaux, Marc Eric Moulichon, Patrick Chopat, Denis Angoulvant, Vincent Bataille, Hervé Le Breton, René Koning, FRANCE ABSORB investigators
- Transcatheter edge-to-edge repair following surgical valve repair with ring implantation: Results from the multicentre “Clip-in-Ring” registry
- Guillaume Leurent, Vincent Auffret, Daniel Grinberg, Robin Le Ruz, Christophe Saint Etienne, Romain Pierrard, Didier Champagnac, Thomas Benard, Guillaume Lecoq, Marc Antoine Arnould, Guillaume Bonnet, Thibault Lhermusier, Amedeo Anselmi, Hervé Corbineau, Erwan Donal, “Clip-in-Ring” registry investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.